Truecaller Travel eSIM Launch Powered by Telness Tech’s Seamless OS
21.5.2026 08:30:00 CEST | Business Wire | Press Release
Telness Tech, the telecom software company behind Seamless OS, today announced that Truecaller’s newly launched Travel eSIM service is powered by its platform.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260520906699/en/
Telness Tech, the telecom software company behind Seamless OS, today announced that Truecaller’s newly launched Travel eSIM service is powered by its platform.
Truecaller, the leading global platform for verifying contacts and blocking unwanted communication, has launched Travel eSIM across 29 countries, marking the company’s move into mobile data services. The launch broadens Truecaller’s platform beyond caller ID and spam protection, and for the first time adds digital consumables to the portfolio.
With more than 500 million people already using Truecaller in their daily communication, Travel eSIM extends that relationship to international travel — a category where users routinely overpay for connectivity or arrive at their destination disconnected.
Travel eSIM is a fully digital mobile data service that activates in minutes, works on iPhone, and offers plans from 1 GB over 7 days to 20 GB over 30 days. Voice and messaging stay in the apps travellers already use — WhatsApp, FaceTime and Signal — running over the same Travel eSIM data connection.
The service is powered by Seamless OS, Telness Tech’s cloud-native telecom platform for launching, managing and scaling digital mobile services.
“Truecaller has built one of the world’s most trusted communication platforms, used by more than 500 million people globally. We are proud that Seamless OS is powering their move into travel eSIM and supporting the launch of a simple, digital mobile data service across 29 countries,” said Martina Klingvall, CEO and Founder of Telness Tech.
Fredrik Kjell, COO at Truecaller, says: “I am delighted that Truecaller is launching an eSIM travel data product to our users. Truecaller is a trusted communications brand across the world and with our scale, we can offer a great product at a competitive price. We are rolling this out on our iPhone client and the web channel, but look forward to expanding with Android and to add support for additional markets.”
The launch reflects a broader shift in telecom, where mobile connectivity is increasingly embedded into trusted digital platforms with strong customer relationships and global distribution.
Markets at launch: Italy, Sweden, Spain, France, Germany, Poland, Portugal, Romania, the Netherlands, Belgium, Ireland, Austria, Finland, the Czech Republic, Denmark, Hungary, the United States, the United Kingdom, Australia, Canada, New Zealand, Switzerland, Norway, Chile, Indonesia, Malaysia, South Africa, Egypt, and Nigeria.
About Truecaller
Truecaller is an essential part of everyday communication for over 500 million active users worldwide, with more than one billion downloads since launch and 68 billion spam and fraud calls identified in 2025 alone. The company is headquartered in Stockholm and has been publicly listed on Nasdaq Stockholm since October 2021. For more information, visit www.truecaller.com.
About Telness Tech
Telness Tech is a telecom software company providing Seamless OS, a cloud-native platform for launching and operating digital mobile services. Seamless OS enables operators, MVNOs and digital brands to launch, manage and scale mobile propositions with reduced complexity and a modern customer experience.
View source version on businesswire.com: https://www.businesswire.com/news/home/20260520906699/en/
Contacts
For more information, please contact:
Truecaller
Agnes Lindberg
Director of Public Relations
+46 704 77 42 93
agnes.lindberg@truecaller.com
Telness Tech
Sebastian Stecki
CMO
+46 73 958 40 86
sebastian.stecki@telnesstech.com
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press Release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press Release
Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press Release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press Release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press Release
Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom